DDInter77 DDInter1376
Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysthymia, and major depression. Amisulpride predominantly works in the limbic system, which explains its relatively lower risk of extrapyramidal adverse effects compared to other atypical antipsychotic agents.[A6752, L32764] Oral tablets of amisulpride is used in European countries as a treatment for acute and chronic schizophrenic disorders, as well as secondary negative symptoms in mental health disorders such as affective disorders, depressive mood, and mental retardation. Amisulpride is also used as an antiemetic agent. In the US, the intravenous formulation of amisulpride is used to treat and prevent postoperative nausea
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Amisulpride {u} (Compound) resembles {v} (Compound) Alizapride
Amisulpride {u} (Compound) binds {v} (Gene) HTR7
Amisulpride {u} (Compound) upregulates {v} (Gene) RGS2
Amisulpride {u} (Compound) causes {v} (Side Effect) Urticaria
Amisulpride {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Amisulpride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Digoxin Immune Fab (Ovine)
Amisulpride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sodium sulfate
Amisulpride {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Amisulpride {u} may lead to a major life threatening interaction when taken with {v} Promethazine
Amisulpride {u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v} Metoclopramide
Amisulpride (Compound) resembles Alizapride (Compound)
Amisulpride (Compound) binds HTR7 (Gene)
Amisulpride (Compound) upregulates RGS2 (Gene)
Amisulpride (Compound) causes Urticaria (Side Effect)
Amisulpride may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Amisulpride may cause a moderate interaction that could exacerbate diseases when taken with Digoxin Immune Fab (Ovine)
Amisulpride may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Amisulpride may lead to a major life threatening interaction when taken with Ribociclib
Amisulpride may lead to a major life threatening interaction when taken with Promethazine
Amisulpride (Compound) resembles Metoclopramide (Compound) and Amisulpride may lead to a major life threatening interaction when taken with Metoclopramide